Published on : Apr 02, 2018
Albany, New York, April 2, 2018: With increasing number of cardiovascular diseases across the globe, the demand for cardiovascular drugs has been also increasing which are used for treating various heart-related dysfunction. A recent study, based on global demand for cardiovascular drugs has found that there are many unmet needs in global cardiovascular drugs market which create huge opportunities for existing players and new entrants in the global market. Market Research Hub (MRH) has publicized this study, titled “Cardiovascular Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 – 2025” to its mega-repository. According to the report evaluations, the global cardiovascular drugs market was valued approximately US$ 80.0 Bn in 2016 and is anticipated to register CAGR of over 1.0% from 2017 to 2025 to reach a value of approximately US$ 91.0 Bn by 2025.
According to WHO, cardiovascular diseases account for 31% deaths globally which are approximately 17.7 million individuals. Out of this 80 % of the CVD deaths are due to stroke and heart attacks. Over the last few decades, a large number of cardiovascular drugs have been discovered thus dramatically changing the treatment of these ailments and of the risks of heart failure and hypertension.
This 241-page research report gives reader precise information related to the cardiovascular drugs market covering current scenario and future prospects through 2025. In the initial section, the market overview of cardiovascular drugs has been explained which demonstrates the market dynamics such as the drivers, restraints, and opportunities that influence the current nature and future status of this market.
For the benefit of the readers, the report provides a complete standpoint on the market’s growth on the basis of revenue in US$ Mn, covering different geographical regions namely Europe, Latin America the Asia Pacific, North America, and MEA. Moving further, the market has been broadly categorized on the basis of drug class, indication, distribution channel. Based on the segmental analysis, research finds major points including;
• Presently, key players are investing in to develop new drugs with better efficacy and fewer side effects. Drug classes used to treat cardiovascular indications such as hyperlipidemia, hypertension are likely to fuel the expansion of the global cardiovascular drugs market from 2017 to 2025.
• Among drug class, anti-clotting agents segment is projected to lead the market and is expected to continue its dominance during the mentioned forecast.
• In terms of geography, Asia Pacific market is highly lucrative. Changing dietary habits and sedentary lifestyle trends in developing markets such as China and India is likely to boost growth of Asia Pacific cardiovascular drugs market.
The study also offers a broad scrutiny of the prominent players and important strategies devised by the companies to succeed in this market. Major companies profiled in the cardiovascular drugs market are AstraZeneca, Takeda Pharmaceuticals Company Limited, Novartis AG, Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Bayer AG, Sanofi, Astellas Pharma, Inc., Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Gilead Sciences, Inc., Johnson & Johnson and Otsuka Holdings Co., Ltd.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1370921
About Market Research Hub
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org